…article continued:
Appendix II
Human Trials
- At MD Anderson Cancer Center, a randomized prospective study gave 39 breast cancer survivors Premarin compared to 319 breast cancer patients not on estrogen. They were followed for 52 months and found no increased risk of recurrence in breast cancer patients on HRT[i].
- A gynecologist at the University of California, Irvine matched 125 breast cancer patients on ERT or HRT with 362 who were not given hormones. There was no increased risk of recurrence in breast cancer patients on hormone therapies[ii].
- A cancer doctor reported a prospective study of 277 breast cancer survivors on ERT for an average of 3.7 years, matched with controls and no increased risk of recurrence was found[iii].
- University of Texas Southwestern Medical Center compared 64 breast cancer survivors on ERT with 563 matched controls not on ERT followed for an average of 12 years and found no increased risk of recurrence with hormonal therapies[iv].
- At the Fred Hutchinson Cancer Research Center at the University of Washington, they reviewed records of 2,755 women diagnosed with cancer between 1977 and 1999, 174 given HRT compared each to 4 controls and followed for an average of 3.7 years finding that HRT in breast cancer survivors had no adverse effect on recurrence or mortality. In fact, breast cancer survivors on HRT had significantly lower breast cancer recurrence rates, breast cancer mortality rates, and overall mortality rates compared to survivors not on hormones[v].
- The Medical College of Wisconsin conducted a review of nine independent observational studies and one randomized controlled trial and found that breast cancer survivors prescribed HRT had no significant risk of recurrence. Their meta-analysis had 717 survivors on HRT compared with 2,545 survivors not on HRT and they found 3% fewer deaths in survivors on ERT compared to 11.4% deaths in survivors not on hormones[vi].
- Researchers from Slovenia from the Institute of Oncology in Ljubljana, compared twenty-one women with breast cancer who were treated with HRT for an average of 28 months with controls for each patient. They found no increased recurrence of breast cancer among women on hormones[vii].
- University of South Wales reproductive endocrinology department followed 90 breast cancer survivors treated with HRT for an average of 18 months followed for an average of 7 years with 180 matched controls found a small but significant reduced recurrence of breast cancer among women on prescribed hormones[viii].
- A gynecologist at the Women’s Health Institute of the Royal Hospital for Women compared 167 women surviving breast cancer on HRT compared with 1,122 similar women not given HRT. There were no increased recurrences of breast cancer even in ER+ patients. A four year follow-up found that there was no increased risk of recurrence in breast cancer patients on HRT[ix].
- A gynecologist from the University of New South Wales published a retrospective observational study of 286 breast cancer patients prescribed HRT compared to 686 breast cancer survivors who didn’t get put on HRT, with some women followed for 26 years. Women on HRT had lower rates of recurrence[x]. They concluded: HRT use for menopausal symptoms by women treated for primary invasive breast cancer is not associated with an increased risk of breast cancer recurrence or shortened life expectancy.
- A cancer doctor at the Hospital Saint-Louis in Paris followed 120 breast cancer survivors prescribed HRT and each patient was compared to two matched control women, and followed for 2.4 years. There was no increased risk of recurrence of breast cancer in survivors on hormones[xi].
- Researchers at the University Central Hospital from Helsinki followed 131 breast cancer survivors, 88 who took ERT and 43 who did not, for 2.6 years. There was no increased risk of recurrence in estrogen survivor users[xii].
- German researchers at the Friederih Alexander University in Erlangen retrospectively reviewed 185 breast cancer patients, 64 who took HRT and 121 who did not. After five years, there was no observed increased risk of recurrence[xiii].
Contact Dr. Berkson
PO Box 203084
Austin, TX 78720
Connect with Dr. Berkson on Social Media!
Facebook: www.facebook.com/Dr.LindseyBerkson/
Instagram: www.instagram.com/dlberkson/
Twitter: www.twitter.com/berksonhealth
More Information
Pick up a copy of my book SEXY BRAIN for more cool stuff and action steps and how to be sexy for years to come.
Join me at www.drlindseyberkson.com for up-to-date health sleuthing about your brain and so much more! Be sure to sign-up for my newsletter while you are there.
In addition to the website you can find my Dr. Berkson’s Best Health Radio podcast on iTunes and Spotify. You can download and listen on the go or at the gym in addition to the comfort of your own home!
Take it Deeper with a Consultation
If you’re concerned about your health or hormones, I’d love for you to schedule a consultation with me to see how I can improve your wellness plan.
Go to www.drlindseyberkson.com/consult-re for more information.
If you’re a practitioner or health coach interested in working 1-on-1 with me, I offer a mentoring program that includes phone, Skype or in-person sessions as well as email access. You can ask me any questions concerning the health of your patients, review patient charts, and learn clinical pearls that only 40 years of practice, best-selling authorship and teaching relicensing courses can teach you. Go to www.drlindseyberkson.com/mentoring for more details.
In Health,
Dr. Lindsey Berkson
About Dr. Berkson
- Best Selling Author of 21 books
- Published Peer Reviewed Original Research with University of Texas Medical School Houston
- Professor at A4M and PCCA for MDs, NPs and pharmacists in Anti-Aging Medicine (hormones, gut health & the environment)
- Research Fellow at Health Sciences Collegium
- Hormone Scholar with Estrogen Think Tank through Tulane University
- Host of Dr. Berkson’s Best Health Podcast
- Blogger – Berkson’s Blog
- Key Note Speaker
